For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
- Parexel Sees Japan as Key Market, Envisions FSP as Growth Pillar
November 7, 2022
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Nichi-Iko to Discontinue Sales of 95 Generics Mainly on Quality Issues
November 4, 2022
- Kissei Grants Taiwan Rights for Linzagolix to Synmosa
November 4, 2022
- Moderna Forging Ahead with mRNA Vaccine Programs for Difficult Viruses; CMV, HIV Jabs in Pipeline: CSO
November 4, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Takeda Provides Fomepizole to Indonesia to Treat Acute Kidney Injury
November 2, 2022
- Lauren Carey to Serve as Interim President of ViiV Japan
November 2, 2022
- Ono Ties Up with Swiss Peer in Immuno-Oncology Drug Discovery
November 2, 2022
- Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
November 1, 2022
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…